Case 35 was diagnosed as having hypertrophic cardiomyopathy. A provocation of the pressure gradient between the left ventricle and aorta is shown in Fig. 2. 1. CAG Of the 21 patients undergoing CAG, 8 patients were excluded from ergonovine challenge: 5 displayed positive coronary stenosis (cases 12, 31, 32, 33 and 34), 1 had VT (case 12), 1 had hypertrophic cardiomyopathy (case 35) and 1 had aortic stenosis (case 36). Of the 13 patients who underwent ergonovine CAG, 9 (69%) showed coronary vasospasm induced by ergonovine as shown in Fig. 3 .
EPS
Eighteen patients underwent EPS. VT induction was performed on 11 cases and VT was induced in 5 patients (cases 9, 12, 13, 14 and 15). In 1 patient who had coronary stenosis, VT was induced only before coronary bypass surgery (Fig. 4) . Two cases who showed nonsustained VT on Holter ECG were negative on VT induction (cases 16 and 17). A total of 10 cases (56%) showed abnormal findings on EPS: 
5) and 2 sick sinus syndrome (cases 4 and 26).
(C) Summary of etiologies ofsyncope revealed by cardiologic assessment Of the 38 syncope cases, 11 patients had VSA and 4 had ischemic heart disease. Of the 7 cases with VT, 9 cases with SSS, 1 case with drug induced SSS, 3 cases with A-V block and 1 case with PSVT, arrhythmias were reproduced in all. There was 1 case showing hypertrophic cardiomyopathy, 1 case with aortic stenosis and 1 case with carotid sinus syndrome. Three patients had combinations of diseases, i.e., VT associated with ischemic heart disease, SSS with VSA and VT with VSA (Tables I and II) .
One case was diagnosed as having ischemic heart disease and was treated with nifedipine and nicorandil. The recurrence of syncope, however, was seen after 5 months of treatment. After all studies, the etiology of syncope could not be determined in case 32. One case had negative EPS and negative ergonovine CAG, and the cause of syncope could not be detected (case 38).
(D) Treatments and follow up Pacemakers were implanted in patients with bradyarrhythmias. Patients in 
DISCUSSION
Syncope and presyncope are disorders that result from a variety of cardiac causes. Kapoor et al showed, using a largely noninvasive approach to the patient with syncope, that a suggestive diagnosis of the cause of syncope is made in approximately half of the patients.11) Patients with a presumed cardiovascular mechanism of syncope were treated empirically and had a 12-month sudden death rate of 24% and a total mortality rate of 30%. Our study with EPS and ergonovine CAG yielded a diagnosis in 95%, and the mortality rate was lower than that in other reported series.3),4),11)-13)
Syncope of cardiac origin can be mainly divided into those caused by arrhythmia, and those caused by mechanical disturbance.
Arrhythmias causing syncope include SSS, A-V block, and tachycardias, such as VT or VF. Holter ECG has facilitated recordings of paroxysmal arrhythmias, however, this method might convey the risk of episodes of lethal arrhythmia. This requires the inclusion of programmed ventricular stimulation as well as bradycardiac approaches to EPS, including His ECG and/or sinus node recovery test.
With obstructions such as aortic stenosis, obstructive hypertrophic cardiomyopathy, or left atrial myxoma, the syncope would be attributed to severely reduced cardiac output with or without vasovagal reflex.1),14) Pulmonary hypertension or tetralogy of Fallot can also be causes of syncope. These diseases can be diagnosed through certain examinations, including chest roentgenogram, echocardiogram and cardiac catheter examination. On the other hand, silent myocardial ischemia or VSA can cause syncope. Myocardial ischemia not only decreases the cardiac output but also causes complications, e.g. severe arrhythmias, such as A-V block, VT or VF. For VSA, provocative tests using ergonovine are useful if repeated Holter ECGs fail to indicate abnormality. We injected ergonovine into both coronaries.10) This method is safe and has a high induction rate.
As a therapy for syncope, pacemaker implantation is popular for bradyarrhythmias and EPS-guided therapy for tachyarrhythmias. The clinical significance of induced polymorphic VT of EPS is still controversial. Cases with ischemic heart disease or VSA undergo A-C bypass and/or are treated with Ca++ antagonists and/or nitro-based agents.
Keeping in mind that in some cases the syncope may be a prodrome of sudden death, these patients should undergo proper diagnosis and therapy including EPS and ergonovine CAG, as well as observation of clinical symptoms.l3), 15) 
